This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1995 Sep;31A(10):1565-6.

doi: 10.1016/0959-8049(95)00390-5.

Prostate cancer--what should be studied?

N D James, J Glaholm

PMID: 7488401
DOI: 10.1016/0959-8049(95)00390-5

Review

Prostate cancer--what should be studied?

N D James et al. Eur J Cancer. 1995 Sep.

. 1995 Sep;31A(10):1565-6.

doi: 10.1016/0959-8049(95)00390-5.

Authors

N D James, J Glaholm

PMID: 7488401
DOI: 10.1016/0959-8049(95)00390-5

No abstract available

PubMed Disclaimer

Comment in

Prostate cancer. An insight into screening and local treatment.
Bolla M, Van Poppel H. Bolla M, et al. Eur J Cancer. 1996 Jul;32A(8):1434-5. doi: 10.1016/0959-8049(96)00094-9. Eur J Cancer. 1996. PMID: 8869112 Clinical Trial. No abstract available.

Comment on

High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group.
Brausi M, Jones WG, Fosså SD, de Mulder PH, Droz JP, Lentz MA, van Glabbeke M, Pawinski A. Brausi M, et al. Eur J Cancer. 1995 Sep;31A(10):1622-6. doi: 10.1016/0959-8049(95)00193-m. Eur J Cancer. 1995. PMID: 7488412 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information